In India, five vaccines have been given approval for emergency use authorization (EUA). The Covid-19 vaccines include Serum Institute's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V, Moderna and now Johnson & Johnson (J&J).
Johnson & Johnson (J&J), an American-based pharma major, has applied to the Central Drugs Standard Control Organization (CDSCO) for permission to conduct a Covid-19 vaccine trial in India among children in the 12-17 age group. The //American pharma J&J said in a statement that it had submitted its application on Tuesday, and that it is "imperative" to ensure all sections of the population, including children, are vaccinated against the coronavirus as quickly as possible to stop the virus.
‘In India, five vaccines have been given approval for emergency use authorization (EUA). The Covid-19 vaccines include Serum Institute's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V, Moderna and now Johnson & Johnson (J&J).’
The single-shot vaccine of J&J is the second Covid-19 vaccine which has already been approved for the Emergency Use Authorization (EUA) through the fast-track approval route by the Drug Controller General of India. In the statement, Johnson & Johnson India also said this was an important step forward in accelerating the availability of its Covid-19 vaccine to help end the pandemic.
Earlier, the Union Health Minister Mansukh Mandaviya had tweeted about the Emergency Use Authorization being given to Johnson & Johnson.
Mandaviya had tweeted, "India expands its vaccine basket! Johnson and Johnson's single-dose COVID-19 vaccine is given approval for Emergency Use in India. Now India has 5 EUA vaccines. This will further boost our nation's collective fight against COVID19."
The five vaccines which have been granted emergency use authorization approval in India include Serum Institute's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V, Moderna and now Johnson & Johnson (J&J).
Advertisement
Source-IANS